Neuromagen Pharma

Company Overview

Snapshot

Founded in May 2021 by Gil Ben-Menachem and Esther Priel, Neuromagen Pharma operates with 1-10 employees. The company has secured $2.5 million across two funding rounds. A significant milestone was achieved in May 2022 when Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate, aimed at slowing the progression of ALS.

Business overview

Neuromagen Pharma is a pharmaceutical company focused on developing innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme crucial in preventing cellular senescence. The company's core mission is to create drugs that delay the onset and progression of neurodegenerative diseases, such as ALS, thereby improving and extending patients' lives. Neuromagen Pharma operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.

Strategic signal

In May 2022, Neuromagen Pharma received. This designation is a critical validation of the drug's potential and provides significant regulatory and commercial advantages, including seven years of marketing exclusivity. This signals strong progress in the company's drug development pipeline and enhances its attractiveness for future clinical trials and potential pharmaceutical partnerships.

Company Intelligence Q&A

What is Neuromagen Pharma's primary focus?

Neuromagen Pharma is a pharmaceutical company dedicated to developing novel small molecules that activate telomerase reverse transcriptase (TERT) to delay the onset and progression of neurodegenerative diseases like ALS.

When did Neuromagen Pharma receive FDA Orphan Drug Designation for AGS-499?

In May 2022, Neuromagen Pharma received FDA Orphan Drug Designation for its AGS-499 drug candidate, which aims to slow the progression of ALS (Amyotrophic Lateral Sclerosis).

What significant grant did Neuromagen Pharma receive?

In March 2022, Neuromagen Pharma received approval from the.

Who are the founders of Neuromagen Pharma?

Neuromagen Pharma was founded by Gil Ben-Menachem and Esther Priel.

What was a key strategic move by Neuromagen Pharma in June 2022?

In June 2022, Neuromagen Pharma established a Scientific Advisory Board and appointed Professor Gal Ifergane, Head of the Neurology Department at Soroka Medical Center, as its first member, strengthening its expertise for upcoming clinical trials.